6 completed, 6 terminated, 5 not yet recruiting, 4 recruiting. 24 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 6, Terminated 6, Not yet recruiting 5, Recruiting 4, Unknown 2, Withdrawn 1 |
| Phase 2 | 8 | Completed 3, Not yet recruiting 2, Recruiting 1, Terminated 1, Unknown 1 |
Follow Multiple Myeloma (MM): new trials by email Literature Review of Multiple Myeloma (MM) trials Research Report on Multiple Myeloma (MM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Not yet recruiting | Umoja Biopharma | 100 | 2026-10-01 | 2026-08-17 |
| Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Sonrotoclax, CM336 (BCMA/CD3 bispecific antibody) - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-08-01 | 2026-07-07 |
| GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders GPRC5D-Targeted PET/CT Imaging - Plasma Cell Disorders, Multiple Myeloma (MM) | Phase 1 | Recruiting | Peking University First Hospital | 50 | 2026-06-25 | 2026-09-28 |
| A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma HLX15-SC-Rd, US-DARZALEX FASPRO®-Rd - Multiple Myeloma (MM) | Phase 1 | Recruiting | Shanghai Henlius Biotech | 258 | 2026-05-25 | 2026-09-24 |
| BR101 in Patients With Relapsed/Refractory Multiple Myeloma BR101 injection - Multiple Myeloma (MM) | Phase 1 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 10 | 2026-04-30 | 2026-04-17 |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects Cemsidomide, Elranatamab - Multiple Myeloma (MM) | Phase 1 | Recruiting | C4 Therapeutics, Inc. | 60 | 2026-02-06 | 2026-10-30 |
| A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies BT02 - Relapsed or Refractory Hematologic Malignancies, Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Biotroy Therapeutics | 116 | 2025-10-01 | 2025-09-17 |
| RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies Allogeneic CAR-T - Relapsed or Refractory B-cell Hematologic Malignancies, B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 27 | 2025-08-01 | 2025-08-13 |
| A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies IDP-121 - Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Recruiting | IDP Discovery Pharma S.L. | 37 | 2023-06-05 | 2025-05-01 |
| CART-38 in Adult AML and MM Patients 3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells - Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) | Phase 1 | Terminated | University of Pennsylvania | 11 | 2023-05-30 | 2025-06-26 |
| Phase I Trial of GR1803 Injection in Patients With RRMM GR1803 injection - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 76 | 2022-05-27 | 2025-08-05 |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) VOB560, MIK665 - Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML) | Phase 1 | Terminated | Novartis Pharmaceuticals | 37 | 2021-06-23 | 2025-10-10 |
| Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma OPC-415 - Multiple Myeloma (MM) | Phase 1 / Phase 2 | Terminated | Otsuka Pharmaceutical Co., Ltd. | 11 | 2021-02-18 | 2026-09-14 |
| Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies Autologous CAR-T cells, Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL) | Phase 1 | Withdrawn | Shanghai Pudong Hospital | 2020-08-01 | 2023-03-01 | |
| A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma ABBV-467 - Multiple Myeloma (MM), Cancer | Phase 1 | Terminated | AbbVie | 8 | 2020-05-19 | 2021-07-26 |
| A Study of WVT078 in Patients With Multiple Myeloma (MM) WVT078, WHG626 - Multiple Myeloma (MM) | Phase 1 | Terminated | Novartis Pharmaceuticals | 56 | 2019-12-05 | 2025-12-24 |
| A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications NKR-2 cells - Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM) | Phase 1 / Phase 2 | Unknown | Celyad Oncology SA | 146 | 2016-12-01 | 2019-09-19 |
| An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma acalabrutinib - Multiple Myeloma (MM) | Phase 1 | Completed | Acerta Pharma BV | 27 | 2015-02-01 | 2020-07-31 |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer Sargramostim, BB-MPI-03, Montanide - Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM) | Phase 1 | Unknown | Benovus Bio, Inc. | 4 | 2015-01-01 | 2016-04-19 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies azacitadine, venetoclax, rituximab / IDEC-C2B8 - Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | AbbVie | 38 | 2014-09-22 | 2021-08-02 |
Showing 20 of 24. Sign in to see all of them.
Multiple Myeloma (24) · Leukemia, Myeloid, Acute (7) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Non-Hodgkin (4) · Recurrence (4) · Myelodysplastic Syndromes (3) · Burkitt Lymphoma (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Bites and Stings (1) · Bronchiolitis Obliterans Syndrome (1) · GATA2 Deficiency (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1)
Blood Protein Disorders (24) · Cardiovascular Diseases (24) · Hematologic Diseases (24) · Hemic and Lymphatic Diseases (24) · Hemorrhagic Disorders (24) · Hemostatic Disorders (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Neoplasms by Histologic Type (24) · Neoplasms, Plasma Cell (24) · Paraproteinemias (24) · Vascular Diseases (24) · Lymphoproliferative Disorders (23) · Neoplasms (23) · Leukemia (10)
Cyclophosphamide (2) · fludarabine (2) · Emulsions (1) · Leukapheresis (1) · Monatide (IMS 3015) (1) · Rituximab (1) · Sirolimus (1) · acalabrutinib (1) · balixafortide (1) · fludarabine phosphate (1) · idelalisib (1) · milatuzumab (1) · sargramostim (1) · venetoclax (1)
AbbVie (2) · Gilead Sciences (2) · Novartis Pharmaceuticals (2) · Acerta Pharma BV (1) · Benovus Bio, Inc. (1) · Biotroy Therapeutics (1) · C4 Therapeutics, Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Celyad Oncology SA (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · IDP Discovery Pharma S.L. (1) · Institut de Recherches Internationales Servier (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Otsuka Pharmaceutical Co., Ltd. (1) · Peking University First Hospital (1)
United States (12) · China (7) · Japan (5) · Australia (4) · Spain (4) · Israel (3) · Belgium (2) · France (2) · Germany (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Finland (1) · Georgia (1) · Hong Kong (1)
Daniel Couriel, M.D. (1) · Enrique Ocio San Miguel, MD, PhD (1) · Jie Jin, PhD (1) · Lei Fan (1) · Lei Kang, M.D, Ph.D (1) · Luke Walker, MD (1) · Nobuhito Sanada (1) · Steven Le Gouill, M.D., Ph.D. (1) · William Wegener, MD, PhD (1) · Ying Wang, MD (1) · Zhiguo Long (1)
PMID 21816833, PMID 24615776, PMID 24615777, PMID 24615778, PMID 29133316, PMID 36764323, PMID 37024520, PMID 37880389
2018 (1)